Lucentis (Ranibizumab) for Retinal Disease: What Patients Need to Know
How Lucentis Works
Lucentis belongs to a class of medications called anti-VEGF therapies. To understand why it works, it helps to first understand what VEGF is and why blocking it protects the retina.
Vascular endothelial growth factor, or VEGF, is a protein the body produces to stimulate the growth of new blood vessels. In a healthy eye, VEGF plays a normal role. In a diseased eye, conditions like macular degeneration or diabetes cause the retina to overproduce VEGF, which triggers the growth of abnormal, fragile blood vessels in or beneath the retina.
These weak vessels leak fluid or blood into the surrounding tissue, damaging the macula, which is the part of the retina responsible for sharp central vision.
Ranibizumab is an antibody fragment engineered to bind tightly to VEGF-A, the specific form of VEGF most responsible for abnormal vessel growth in the eye. Once bound, ranibizumab prevents VEGF-A from attaching to receptors on blood vessel walls, which slows abnormal vessel growth and reduces leakage. Over time, fluid in the retina decreases and retinal tissue stabilizes.
The FDA has approved Lucentis for five specific retinal conditions, all of which involve VEGF-driven damage. These conditions are:
- Wet age-related macular degeneration (wet AMD)
- Diabetic macular edema (DME)
- Diabetic retinopathy (DR)
- Macular edema following retinal vein occlusion (RVO)
- Myopic choroidal neovascularization (myopic CNV)
Your retina specialist will confirm whether Lucentis is the right treatment option for your specific diagnosis and overall eye health.
What the Clinical Evidence Shows
Lucentis has been studied in large, rigorous clinical trials over many years. The evidence from these trials helped transform how retina specialists approach vision-threatening diseases.
The MARINA trial enrolled more than 700 patients with wet AMD who received either monthly ranibizumab injections or sham injections for two years. At 12 months, patients in the treatment group gained an average of 6 to 7 letters of visual acuity, while the control group lost an average of more than 10 letters. This was the first time any treatment had been shown to improve vision in wet AMD rather than simply slowing its decline, which marked a turning point in retinal care.
The ANCHOR trial compared ranibizumab to photodynamic therapy (PDT), which was the leading treatment for wet AMD at the time. Results showed that up to 40 percent of patients receiving ranibizumab gained 15 or more letters of visual acuity, far surpassing what PDT achieved. These findings confirmed that anti-VEGF therapy represented a fundamentally more effective approach to treating certain forms of wet AMD.
The SEVEN-UP study followed patients from the original MARINA and ANCHOR trials for seven years after their initial treatment period. Many patients maintained meaningful vision gains over that time. However, the study also found that ongoing treatment is typically necessary. Patients who stopped injections tended to lose some of the vision improvement they had gained, which underscores why continued monitoring and treatment matter.
What the Injection Experience Is Like
Intravitreal injections, meaning injections delivered directly into the eye, are a routine part of retinal care. Our team takes careful steps to keep the experience as comfortable as possible.
Before the procedure begins, your specialist applies anesthetic drops to numb the surface of the eye. An antiseptic solution is then used to clean the eye and lower the risk of infection. Some patients receive a small additional numbing medication around the eye as well. The entire preparation process takes only a few minutes.
The injection itself takes only a few seconds. A very thin needle delivers the medication through the white part of the eye into the vitreous, which is the gel-filled space inside the eye. Most patients describe the sensation as brief pressure rather than sharp pain. Including preparation and a short observation period afterward, the full appointment typically lasts between 30 minutes and one hour.
Mild redness, a gritty sensation, or temporary blurred vision are common in the hours following the injection and usually resolve on their own within a day. You can return to most routine activities the same day, but you should avoid rubbing your eye, swimming, or spending time in dusty environments for a few days. Artificial tears can help if your eye feels dry or irritated. Arrange for someone to drive you home from the appointment.
Treatment Schedule and Frequency
How often you receive Lucentis depends on your diagnosis, how your retina responds, and the approach your specialist recommends. Treatment schedules are tailored to each patient.
Lucentis was originally studied and approved as a monthly injection. For wet AMD, diabetic macular edema, and retinal vein occlusion, monthly dosing was the foundation of the clinical trial protocols that produced strong visual outcomes. Monthly treatment provides consistent suppression of VEGF activity and is still used for some patients.
Many retina specialists now use a treat-and-extend strategy. After an initial series of monthly injections, the interval between treatments is gradually lengthened based on how the retina is responding. Optical coherence tomography (OCT) scans, which produce detailed cross-sectional images of the retina, are used at each visit to check for fluid or swelling. If the retina remains stable, the interval between injections may extend to six, eight, or more weeks. If fluid returns, the interval is shortened until control is reestablished.
Research has consistently shown that patients who keep their treatment schedule tend to have better long-term visual outcomes. Skipping injections can allow fluid to return and retinal damage to progress, even during periods when vision feels unchanged. If you ever need to reschedule an appointment, contact your retina specialist promptly so that any gap in treatment can be minimized.
Benefits and Risks of Lucentis
Like any medical treatment, Lucentis offers meaningful benefits along with a small but real set of risks. Understanding both helps you make informed decisions about your care.
Lucentis was the first medication proven to improve vision, not just stabilize it, in wet AMD. In clinical trials, the majority of patients maintained or improved their vision over two years of treatment. Some patients experienced gains meaningful enough to resume activities such as reading, recognizing faces, or driving. The primary goals of treatment are to reduce fluid in the retina, stabilize vision, and protect the gains achieved over time.
The most frequently reported side effects are mild and related to the injection itself. These include temporary eye redness at the injection site, a brief sensation of pressure or discomfort, floaters, and blurred vision. Most of these effects resolve on their own within a few hours to a few days and do not require further treatment.
Serious complications following intravitreal injections are uncommon but possible. These include eye infection (a condition called endophthalmitis), retinal detachment, significant increase in eye pressure, and bleeding inside the eye. Seek immediate care from your retina specialist or an emergency room if you experience sudden vision loss, severe eye pain, a large increase in floaters, flashes of light, or a shadow or curtain across your vision following an injection.
How Lucentis Compares to Other Anti-VEGF Treatments
Lucentis was the first FDA-approved anti-VEGF injection for retinal disease, but several other medications have since become available. Your retina specialist will recommend the option that best fits your condition and treatment goals.
Several alternatives to Lucentis are now widely used. Eylea (aflibercept) offers dosing intervals of four to eight weeks. Eylea HD, a higher-dose formulation, may extend intervals to 8 to 16 weeks in appropriate patients. Vabysmo (faricimab) targets both VEGF and a second protein called angiopoietin-2, and may also allow longer intervals between injections. Avastin (bevacizumab) is used off-label for retinal conditions and is often chosen for its lower cost. Each medication has its own approved uses, dosing schedule, and evidence profile.
Two biosimilar versions of ranibizumab are now FDA-approved: Byooviz (ranibizumab-nuna) and Cimerli (ranibizumab-eqrn). Biosimilars contain the same active ingredient as the original medication and must demonstrate to the FDA that they are highly similar in safety and effectiveness. Real-world data involving thousands of injections have shown outcomes consistent with the original Lucentis. Cimerli carries an interchangeable biosimilar designation, meaning it may be substituted for Lucentis in certain circumstances. Your specialist can explain whether a biosimilar is an appropriate option for you.
Ongoing Monitoring and When to Seek Urgent Care
Regular follow-up is an essential part of retinal treatment. Our team monitors your retina closely between appointments and wants you to know when to seek care right away.
At each visit, your specialist will typically perform vision testing and retinal imaging using OCT. These scans show the layers of the retina in detail and reveal any fluid or structural changes. The results directly guide decisions about your treatment schedule, including whether to maintain, extend, or shorten the interval between injections. Regular appointments also allow your specialist to monitor overall eye health beyond the treated condition.
Certain vision changes require prompt evaluation regardless of when your next scheduled appointment falls. Contact your retina specialist or go to an emergency room right away if you notice sudden vision loss in one eye, a new shadow or curtain across any part of your vision, a dramatic increase in floaters, flashes of light, or severe eye pain. These symptoms can indicate complications that need to be addressed without delay.
Frequently Asked Questions
Below are answers to questions we commonly hear from patients considering or currently receiving Lucentis treatment.
For most patients, Lucentis is a long-term treatment rather than a short-term course. The underlying conditions it treats, such as wet AMD and diabetic macular edema, are chronic and require ongoing management. While a treat-and-extend approach may reduce injection frequency over time, stopping treatment entirely often allows fluid to return and vision to decline. Your retina specialist will reassess your schedule regularly and adjust based on how your retina is responding.
Lucentis can improve vision in many patients, particularly when treatment begins before severe damage has occurred. However, it works best as a tool for stabilizing and protecting vision that remains, rather than reversing long-standing retinal damage. Some patients do regain meaningful vision, while others see their primary benefit as preventing further decline. Starting treatment early generally leads to better outcomes, which is why prompt evaluation matters when symptoms first appear.
Biosimilars approved by the FDA are required to demonstrate that they are highly similar to the original product with no clinically meaningful differences in safety or effectiveness. Published real-world data on ranibizumab biosimilars have shown results consistent with the original medication across thousands of injections. That said, your retina specialist is the right person to determine whether the original Lucentis or a biosimilar is most appropriate for your individual situation, taking insurance, cost, and clinical factors into account.
Yes. Lucentis has FDA approval and strong clinical evidence for diabetic macular edema, diabetic retinopathy, retinal vein occlusion with macular edema, and myopic choroidal neovascularization. Clinical trials for diabetic macular edema showed significant improvements in visual acuity compared to controls, making anti-VEGF therapy a cornerstone of diabetic eye disease treatment. If you have been diagnosed with any of these conditions, a consultation with a retina specialist can clarify whether ranibizumab is appropriate for your case.
Contact our office as soon as you realize you need to reschedule. Missing even one injection can allow fluid to return to the retina and potentially reverse vision gains. The sooner you reschedule, the better. Your specialist will assess your retina at the next visit with imaging and determine whether any adjustments to your treatment plan are needed based on what they find.
Schedule a Retina Consultation at Rhode Island Eye Institute
Our fellowship-trained retina specialists, including Gaurav Gupta, M.D. and Pranjal Thakuria, M.D., bring deep expertise in diagnosing and treating the full range of retinal conditions. Rhode Island Eye Institute serves patients throughout Rhode Island and southeastern Massachusetts with advanced diagnostic technology and individualized treatment plans. If you have been diagnosed with a retinal condition or have concerns about your central vision, we encourage you to schedule a consultation so we can evaluate your retina and discuss the options available to protect your sight.